Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 1
2005 3
2006 2
2007 1
2008 3
2011 1
2012 1
2013 1
2016 1
2018 2
2019 1
2020 1
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer.
Salaroglio IC, Belisario DC, Akman M, La Vecchia S, Godel M, Anobile DP, Ortone G, Digiovanni S, Fontana S, Costamagna C, Rubinstein M, Kopecka J, Riganti C. Salaroglio IC, et al. Among authors: costamagna c. J Exp Clin Cancer Res. 2022 Aug 11;41(1):243. doi: 10.1186/s13046-022-02447-6. J Exp Clin Cancer Res. 2022. PMID: 35953814 Free PMC article.
Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I, Gazzano E, Jean SR, Audrito V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I, Mungo E, Hattinger CM, Deaglio S, Kelley SO, Serra M, Riganti C. Buondonno I, et al. Among authors: costamagna c. Mol Cancer Ther. 2016 Nov;15(11):2640-2652. doi: 10.1158/1535-7163.MCT-16-0048. Epub 2016 Jul 27. Mol Cancer Ther. 2016. PMID: 27466354
Corrigendum to 'Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein' [Pharmacol. Res. 175 (2022) 105975].
Abd-Ellatef GEF, Gazzano E, El-Desoky AH, Hamed AR, Kopecka J, Belisario DC, Costamagna C, Marie MAS, Fahmy SR, Abdel-Hamid AZ, Riganti C. Abd-Ellatef GEF, et al. Among authors: costamagna c. Pharmacol Res. 2023 Mar;189:106708. doi: 10.1016/j.phrs.2023.106708. Epub 2023 Mar 2. Pharmacol Res. 2023. PMID: 36868967 Free article. No abstract available.
Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.
Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C. Salaroglio IC, et al. Among authors: costamagna c. Mol Pharm. 2019 Aug 5;16(8):3361-3373. doi: 10.1021/acs.molpharmaceut.9b00018. Epub 2019 Jul 2. Mol Pharm. 2019. PMID: 31265310 Free article.
26 results